Celltrion
FDA Approves Herzuma for Breast Cancer
The FDA approved Herzuma, a HER2/neu receptor antagonist biosimilar to Herceptin for breast cancer treatment.
DECEMBER 17, 2018
FDA Approves Truxima, First Biosimilar to Rituxan
Truxima can be used to treat three types of adults with non-Hodgkin lymphoma.
NOVEMBER 29, 2018
New Noninferiority Data for Biosimilar Infliximab
Biosimilar infliximab is not inferior to the originator product, Remicade in treating rheumatoid arthritis and ...
OCTOBER 20, 2016
Load more